Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
George J Wan, John Niewoehner & Kyle Hayes. (2023) Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence. ClinicoEconomics and Outcomes Research 15, pages 499-512.
Read now
Read now
Bingcao Wu, Gaurav Deshpande, Tao Gu, Breanna Popelar, Michael Philbin & George J. Wan. (2017) Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis. Journal of Medical Economics 20:11, pages 1170-1177.
Read now
Read now
Articles from other publishers (5)
Jonathan Lim, Carl Samuelsen, Amanda Golembesky, Sulena Shrestha, Li Wang & Ingolf Griebsch. (2019) Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. Future Oncology 15:13, pages 1493-1504.
Crossref
Crossref
Rohit Aggarwal & Chester V Oddis. (2019)
Response to: ’Elephant in the room' by Hartung
et al
. Annals of the Rheumatic Diseases 78:2, pages e12-e12.
Crossref
Crossref
Winnie W. Nelson, Michael J. Philbin, Jack R. Gallagher, Kylee Heap, Susan Carroll & George J. Wan. (2017) A Retrospective Medical Record Review of Utilization Patterns and Medical Resource Use Associated with Repository Corticotropin Injection among Patients with Rheumatologic Diseases in the United States. Rheumatology and Therapy 4:2, pages 465-474.
Crossref
Crossref
Michael Philbin, John Niewoehner & George J. Wan. (2017) Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications. Advances in Therapy 34:8, pages 1775-1790.
Crossref
Crossref
. (2017) Corticotropin reduces resource use and costs of DM/PM. PharmacoEconomics & Outcomes News 779:1, pages 11-11.
Crossref
Crossref